NCT02576301View on ClinicalTrials.gov

Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

October 31, 2019

Study Completion Date

October 31, 2020

Conditions
Acute Myelogenous LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

Phase 1 - OXi4503

Determination of MTD of OXi4503

DRUG

Phase 1 - OXi4503 + cytarabine

Determination of MTD of the combination of OXi4503 + cytarabine

DRUG

Phase 2 - OXi4503 + cytarabine

Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with AML

DRUG

Phase 2 - OXi4503 + cytarabine

Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with MDS

Trial Locations (4)

32610

RECRUITING

University of Florida, Gainesville

33136

RECRUITING

University of Miami Sylvester Comprehensive Cancer Center, Miami

66205

RECRUITING

University of Kansas Cancer Center and Medical Pavilion, Westwood

90095

RECRUITING

David Geffen School of Medicine at UCLA, Los Angeles

Sponsors
All Listed Sponsors
lead

Mateon Therapeutics

INDUSTRY